Skip to content

Yew Bio-Pharm Group, Inc.: 10-Q filed 2017-11-13

What Yew Bio-Pharm Group, Inc. reported in its quarterly report filed 2017-11-13 (fiscal Q3 2017): 38 published measures, 107 facts as tagged in accession 0001213900-17-011844.

This filing

Form
10-Q (quarterly report)
Filed
2017-11-13
Fiscal period
fiscal Q3 2017
Accession
0001213900-17-011844 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Yew Bio-Pharm Group, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-09-3059,859,554USD
At 2016-12-3146,195,261USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-09-308,279,420USD
At 2016-12-317,619,158USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-09-3051,580,134USD
At 2016-12-3138,576,103USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-09-301,339,673USD
At 2016-12-31278,991USD
At 2016-09-30964,701USD
At 2015-12-31681,608USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-30614,407USD92
2017-01-01 to 2017-09-3011,039,824USD273
2016-07-01 to 2016-09-301,080,538USD92
2016-01-01 to 2016-09-303,437,145USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-09-307,742USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2017-07-01 to 2017-09-3011,564,915USD92
2017-01-01 to 2017-09-3035,044,755USD273
2016-07-01 to 2016-09-3014,667,099USD92
2016-01-01 to 2016-09-3039,347,578USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-09-3038,114,448USD
At 2016-12-3127,074,624USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2017-07-01 to 2017-09-3051,875,000shares92
2017-01-01 to 2017-09-3051,875,000shares273
2016-07-01 to 2016-09-3051,875,000shares92
2016-01-01 to 2016-09-3051,875,000shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2017-07-01 to 2017-09-3054,561,533shares92
2017-01-01 to 2017-09-3053,965,264shares273
2016-07-01 to 2016-09-3051,893,930shares92
2016-01-01 to 2016-09-3051,875,000shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2017-07-01 to 2017-09-300.01USD/shares92
2017-01-01 to 2017-09-300.21USD/shares273
2016-07-01 to 2016-09-300.02USD/shares92
2016-01-01 to 2016-09-300.07USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2017-07-01 to 2017-09-300.01USD/shares92
2017-01-01 to 2017-09-300.2USD/shares273
2016-07-01 to 2016-09-300.02USD/shares92
2016-01-01 to 2016-09-300.07USD/shares274

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2017-07-01 to 2017-09-30610USD92
2017-01-01 to 2017-09-30610USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-09-30583,542USD
At 2016-12-31692,116USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-09-3094,177USD273
2016-01-01 to 2016-09-30245,518USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-07-01 to 2017-09-30489,000USD92
2017-01-01 to 2017-09-3011,000,325USD273
2016-07-01 to 2016-09-301,119,515USD92
2016-01-01 to 2016-09-303,505,580USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-09-3041,721,379USD
At 2016-12-3133,793,298USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-09-307,927,778USD
At 2016-12-317,498,185USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2017-09-309,823,740USD
At 2016-12-314,558,234USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2017-09-3011,743,961USD
At 2016-12-3114,467,852USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-07-01 to 2017-09-30260,916USD92
2017-01-01 to 2017-09-30859,234USD273
2016-07-01 to 2016-09-30299,517USD92
2016-01-01 to 2016-09-30956,674USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2017-09-309,362,578USD
At 2016-12-3110,296,792USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2017-07-01 to 2017-09-30749,916USD92
2017-01-01 to 2017-09-3011,859,559USD273
2016-07-01 to 2016-09-301,419,032USD92
2016-01-01 to 2016-09-304,462,254USD274

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2017-07-01 to 2017-09-3010,814,999USD92
2017-01-01 to 2017-09-3023,185,196USD273
2016-07-01 to 2016-09-3013,248,067USD92
2016-01-01 to 2016-09-3034,885,324USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-09-3051,875,000shares
At 2016-12-3151,875,000shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2017-09-309,748,201USD
At 2016-12-319,654,024USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-09-30-96,678USD
At 2016-12-31-1,966,708USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-09-3092,442USD
At 2016-12-3175,743USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2017-07-01 to 2017-09-30615,017USD92
2017-01-01 to 2017-09-3011,040,434USD273
2016-07-01 to 2016-09-301,080,538USD92
2016-01-01 to 2016-09-303,437,145USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2017-07-01 to 2017-09-301,404,956USD92
2017-01-01 to 2017-09-3012,909,854USD273
2016-07-01 to 2016-09-30882,413USD92
2016-01-01 to 2016-09-302,340,351USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-30196,569USD92
2017-01-01 to 2017-09-30794,556USD273
2016-07-01 to 2016-09-30293,850USD92
2016-01-01 to 2016-09-30938,920USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-01-01 to 2017-09-3050,944USD273
2016-01-01 to 2016-09-3089,410USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2017-07-01 to 2017-09-30178,122USD92
2017-01-01 to 2017-09-30179,559USD273
2016-07-01 to 2016-09-30390USD92
2016-01-01 to 2016-09-3040,219USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2017-07-01 to 2017-09-30126,017USD92
2017-01-01 to 2017-09-3040,109USD273
2016-07-01 to 2016-09-30-38,977USD92
2016-01-01 to 2016-09-30-68,435USD274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2017-01-01 to 2017-09-3018,197USD273
2016-01-01 to 2016-09-306,460USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-09-30-3,276,466USD273
2016-01-01 to 2016-09-304,873,750USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-09-303,278,467USD273
2016-01-01 to 2016-09-3010,567,924USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-09-30-1,698,340USD273
2016-01-01 to 2016-09-301,660,178USD274

Inspect the source

Entity
Yew Bio-Pharm Group, Inc. / CIK 0001548240
Captured
SEC response SHA-256
42d239bf62595328b4b0f26c5a40397396731e01ab6dfcaf5b29c1b41870e6be

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001548240.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))